Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,961 to 3,980 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| 3M Skin and Nasal Antiseptic vs Bactroban Nasal: Measure Rate of Staphylococcus Aureus Resistance to Mupirocin. | 21 of 842 24 of 855 | -0.3 points -1.9 to 1.3 | 1,697 | NCT01313182 Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial | 322 of 871 325 of 825 | -2.4 points -7.0 to 2.2 | 1,696 | NCT01499511 Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events, as Defined, or Death. | 110 of 849 119 of 846 | -1.1 points -4.4 to 2.2 | 1,695 | NCT00013611 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: All-cause Mortality | 81 of 849 77 of 846 | 0.4 points -2.3 to 3.2 | 1,695 | NCT00013611 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Serious Disease Progression Events or Death | 19 of 849 28 of 846 | -1.1 points -2.7 to 0.5 | 1,695 | NCT00013611 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: New or Recurrent Disease Progression Events | 49 of 849 66 of 846 | -2.0 points -4.5 to 0.4 | 1,695 | NCT00013611 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: Grade 4 Clinical Events | 203 of 849 186 of 846 | 1.9 points -2.1 to 5.9 | 1,695 | NCT00013611 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) |
| Proleukin Plus Antiretroviral Therapy vs Antiretroviral Therapy Only: serious adverse events | 203 of 849 186 of 846 | 1.9 points -2.1 to 5.9 | 1,695 | NCT00013611 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) |
| ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Undergone Coronary/Peripheral Re-vascularisation Procedures Since the End of the ASCOT Trial | 39 of 872 33 of 822 | 0.5 points -1.5 to 2.4 | 1,694 | NCT01499511 Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study |
| With History of Treatment Prior to Sertraline vs Without History of Treatment Prior to Sertraline: Factors Considered to Affect the Efficacy of Sertraline: History of Treatment Prior to Administration of Sertraline Hydrochloride | 398 of 489 1,046 of 1,202 | -5.6 points -9.7 to -1.8 | 1,691 | NCT00605865 Drug Use Investigation of Jzoloft. |
| Cervarix Pooled Group vs Engerix-B Pooled Group: Number of Male Subjects Reporting Medically Significant Conditions (MSCs), in a Subset of Subjects | 47 of 643 76 of 1,047 | 0.1 points -2.4 to 2.7 | 1,690 | NCT00534638 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents |
| Absorb BVS vs XIENCE: Landmark Analysis on TLF and Components | 60 of 1,108 38 of 580 | -1.1 points -3.7 to 1.2 | 1,688 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| 17P (Hydroxyprogesterone Caproate Injection) vs Vehicle: Preterm Birth <35 Weeks Gestation | 122 of 1,113 66 of 574 | -0.5 points -3.9 to 2.5 | 1,687 | NCT01004029 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery |
| TBP-PI-HBr vs Imipenem-cilastatin: deaths from any cause | 2 of 843 2 of 844 | 0.0 points -0.6 to 0.6 | 1,687 | NCT06059846 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| TBP-PI-HBr vs Imipenem-cilastatin: serious adverse events | 29 of 843 22 of 844 | 0.8 points -0.8 to 2.5 | 1,687 | NCT06059846 A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| Promus Element Plus vs SYNERGY: serious adverse events | 262 of 838 265 of 846 | -0.1 points -4.5 to 4.4 | 1,684 | NCT01665053 The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) |
| INV_MMR Group vs COM_MMR Group: Number of Subjects Reporting Any Fever | 350 of 1,126 179 of 555 | -1.2 points -6.0 to 3.5 | 1,681 | NCT02184572 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age |
| LR-TRUS vs UHR-TRUS: serious adverse events | 3 of 839 3 of 837 | -0.0 points -0.7 to 0.7 | 1,676 | NCT02079025 Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer |
| BCG-Denmark vs Control: deaths from any cause | 1 of 838 3 of 838 | -0.2 points -0.9 to 0.4 | 1,676 | NCT04542330 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic |
| BCG-Denmark vs Control: serious adverse events | 78 of 838 63 of 838 | 1.8 points -0.9 to 4.5 | 1,676 | NCT04542330 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic |
Code
curl "https://conductscience.org/api/comparisons/v1?page=199"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=199
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01313182-4bd46373",
"title": "3M Skin and Nasal Antiseptic vs Bactroban Nasal: Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.",
"summary": "21 of 842 against 24 of 855; risk difference -0.3 points, 95% interval -1.9 to 1.3; NCT01313182, Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin",
"record": "/library/comparisons/NCT01313182-4bd46373",
"nct_id": "NCT01313182",
"kind": "outcome",
"participants": 1697,
"risk_difference": {
"value": -0.0031295578613993423,
"lower": -0.019000328432907176,
"upper": 0.012666297651379412
},
"group_1": "21 of 842",
"group_2": "24 of 855",
"difference": "-0.3 points",
"interval": "-1.9 to 1.3",
"trial_title": "Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin"
},
{
"id": "NCT01499511-32241691",
"title": "ASCOT Participants Amlodipine vs ASCOT Participants Atenolol: Number of Participants Who Have Developed Diabetes Since the End of the ASCOT Trial",
"summary": "322 of 871 against 325 of 825; risk difference -2.4 points, 95% interval -7.0 to 2.2; NCT01499511, Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study",
"record": "/library/comparisons/NCT01499511-32241691",
"nct_id": "NCT01499511",
"kind": "outcome",
"participants": 1696,
"risk_difference": {
"value": -0.024249382458337687,
"lower": -0.07036854018152244,
"upper": 0.021954368500851543
},
"group_1": "322 of 871",
"group_2": "325 of 825",
"difference": "-2.4 points",
"interval": "-7.0 to 2.2",
"trial_title": "Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=200",
"request_id": "smYweJABPaJLAJb2"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant